Profile data is unavailable for this security.
About the company
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
- Revenue in CHF (TTM)0.00
- Net income in CHF-12.49m
- Incorporated1996
- Employees--
- LocationSpexis AGHegenheimermattweg 125ALLSCHWIL 4123SwitzerlandCHE
- Phone+41 615671600
- Fax+41 615671601
- Websitehttps://spexisbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanogroup SA | 467.00 | -1.82m | 4.67m | -- | -- | 4.51 | -- | 9,998.98 | -0.3926 | -0.3926 | 0.0001 | 0.2228 | 0.0002 | 17.60 | 0.0349 | -- | -56.82 | -23.18 | -67.19 | -26.06 | -47,764.85 | -278.03 | -391,395.10 | -1,567.57 | 0.5186 | -2,409.12 | 0.00 | -- | -98.55 | -55.07 | -840.84 | -- | -8.99 | -- |
| Scandion Oncology A/S | 0.00 | -5.17m | 4.68m | 4.00 | -- | 1.14 | -- | -- | -1.52 | -1.52 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -63.25 | -45.09 | -76.67 | -52.65 | -- | -- | -- | -- | -- | -- | 0.0158 | -- | -- | -- | 48.89 | -- | -- | -- |
| Stem Cells Spin SA | 96.98k | -35.70k | 4.78m | 1.00 | -- | 2.78 | 22.20 | 49.29 | -0.0037 | -0.0037 | 0.0101 | 0.1797 | 0.0295 | 0.0746 | 1.57 | 419,330.00 | -1.09 | -1.14 | -1.78 | -1.93 | 89.36 | 94.37 | -36.81 | -45.36 | 0.0364 | -33.81 | 0.0153 | -- | 68.84 | -4.37 | -680.05 | -- | -52.67 | -- |
| Pila Pharma AB | 123.73k | -839.79k | 4.83m | 1.00 | -- | 8.57 | -- | 39.03 | -0.5304 | -0.5304 | 0.0767 | 0.28 | 0.1513 | -- | 6.11 | 1,463,020.00 | -102.68 | -108.88 | -122.66 | -121.45 | -127.88 | -42.67 | -678.73 | -1,577.64 | -- | -159.47 | 0.104 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| Genxone SA | 553.83k | -860.14k | 4.85m | -- | -- | 1.40 | -- | 8.76 | -1.13 | -1.13 | 0.7265 | 4.54 | 0.1358 | 13.39 | 5.04 | -- | -21.09 | 14.58 | -22.04 | 16.46 | -23.18 | 48.42 | -155.31 | 20.41 | 16.91 | -- | 0.0039 | -- | -77.38 | 111.39 | -874.87 | -- | -28.78 | -- |
| Orphazyme A/S | 0.00 | -3.44m | 4.93m | 1.00 | -- | 2.62 | -- | -- | -737.75 | -737.75 | 0.00 | 403.34 | 0.00 | -- | -- | 0.00 | -68.42 | -76.08 | -94.18 | -105.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.00 | -- | -- | -- |
| Spago Nanomedical AB (publ) | 123.90k | -2.91m | 5.11m | 12.00 | -- | 1.76 | -- | 41.26 | -0.2454 | -0.2454 | 0.0107 | 0.1525 | 0.0324 | -- | 9.90 | 112,692.30 | -76.02 | -20.19 | -90.21 | -20.97 | 115.84 | -- | -2,349.01 | -4,853.45 | -- | -- | 0.00 | -- | 14.14 | -- | -7.72 | -- | -- | -- |
| PCI Biotech Holding ASA | 253.15k | -1.72m | 5.15m | 7.00 | -- | 1.56 | -- | 20.35 | -0.5443 | -0.5443 | 0.0801 | 1.05 | 0.0556 | -- | 0.6848 | 427,142.80 | -37.78 | -36.44 | -41.97 | -40.14 | -- | -- | -679.43 | -1,055.43 | -- | -- | 0.0081 | -- | -37.05 | -20.78 | 63.13 | -- | -- | -- |
| Spexis AG | 0.00 | -12.49m | 5.26m | -- | -- | 0.236 | -- | -- | -0.2547 | -0.2547 | 0.00 | 0.3296 | 0.00 | -- | -- | -- | -35.86 | -50.41 | -44.63 | -62.27 | -- | -- | -- | -892.14 | -- | -- | 0.3098 | -- | -- | -- | -56.41 | -- | -62.03 | -- |
| NUTEX Befektetesi Nyrt | 1.15k | 186.06k | 5.33m | 1.00 | 28.55 | 0.3973 | 28.60 | 4,657.26 | 0.4955 | 0.4955 | 0.003 | 35.62 | 0.00009 | -- | 0.0148 | -- | 1.39 | -1.40 | 1.40 | -1.41 | 50.00 | -- | 16,242.67 | -3,393.18 | 702.09 | -- | 0.00 | -- | 0.00 | -44.77 | 952.46 | -- | -- | -- |
| Combigene AB | 468.87k | -3.02m | 5.44m | 8.00 | -- | 0.5526 | -- | 11.61 | -1.80 | -1.80 | 0.28 | 5.88 | 0.0398 | -- | 2.63 | 693,015.00 | -25.58 | -13.00 | -26.56 | -14.58 | -- | -- | -643.32 | -58.77 | -- | -- | 0.00 | -- | -79.23 | 268.58 | -479.27 | -- | -24.02 | -- |
| Pure Biologics SA | 25.21k | -7.34m | 5.49m | 53.00 | -- | 1.82 | -- | 217.90 | -11.15 | -11.15 | 0.0377 | 4.05 | 0.0023 | -- | 0.1026 | 1,135.42 | -66.46 | -48.68 | -81.74 | -83.38 | -3,960.55 | 38.81 | -29,097.25 | -195.73 | -- | -11.41 | 0.7606 | -- | 160.63 | -7.58 | -117.62 | -- | -- | -- |
| BSF Enterprise PLC | 14.86k | -1.72m | 5.64m | 4.00 | -- | 1.01 | -- | 379.33 | -0.0159 | -0.0159 | 0.0001 | 0.047 | 0.0028 | 2.11 | 0.0837 | 3,235.00 | -32.30 | -- | -34.46 | -- | -451.16 | -- | -11,600.08 | -- | 8.16 | -154.86 | 0.0313 | -- | -- | -- | -61.40 | -- | -- | -- |
| Double Bond Phrmcutcl Intrntnl AB (publ) | 115.89k | -1.47m | 5.64m | 10.00 | -- | 11.88 | -- | 48.66 | -0.1837 | -0.1837 | 0.0136 | 0.0556 | 0.1016 | -- | 18.59 | 137,033.00 | -128.49 | -80.90 | -198.98 | -106.45 | -241.22 | -686.41 | -1,265.24 | -1,360.03 | -- | -217.55 | 0.00 | -- | 10.25 | 135.07 | -14.36 | -- | -- | -- |
| Immunovia AB (publ) | 102.50k | -22.05m | 5.78m | 11.00 | -- | 1.57 | -- | 56.42 | -6.06 | -6.06 | 0.0276 | 0.9648 | 0.0075 | 58.23 | 14.96 | 110,181.80 | -160.93 | -41.33 | -194.89 | -44.24 | -5,523.76 | -7,553.76 | -21,512.13 | -20,879.29 | 2.03 | -- | 0.1675 | -- | 37.55 | 36.48 | -84.09 | -- | -50.93 | -- |
| ViroGates A/S | 756.72k | -1.68m | 5.87m | 10.00 | -- | 3.32 | -- | 7.76 | -6.00 | -6.00 | 1.44 | 2.08 | 0.3344 | 0.316 | 3.64 | 573,300.00 | -74.36 | -46.58 | -80.05 | -52.09 | 77.20 | 77.91 | -222.40 | -238.01 | 10.45 | -19.08 | 0.2833 | -- | -45.01 | 10.98 | -25.40 | -- | -- | -- |
Data as of May 16 2024. Currency figures normalised to Spexis AG's reporting currency: Swiss Franc CHF
0.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 405.18k | 0.60% |
| UBS Asset Management Switzerland AGas of 02 Apr 2024 | 121.14k | 0.18% |
| Z�rcher Kantonalbank (Investment Management)as of 28 Mar 2024 | 77.22k | 0.11% |
| Credit Suisse AGas of 31 Jan 2024 | 25.45k | 0.04% |
| Pictet Asset Management SAas of 31 Jan 2024 | 18.33k | 0.03% |
| BlackRock Asset Management Schweiz AGas of 04 Apr 2024 | 18.00k | 0.03% |
| LLB Asset Management AGas of 31 Mar 2024 | 2.35k | 0.00% |
| State Street Global Advisors France SAas of 31 Mar 2024 | 1.50k | 0.00% |
More ▼
Data from 31 Dec 2023 - 09 May 2024Source: FactSet Research Systems Inc.
